X0202 SCHEDULE 13G 0001665241 XXXXXXXX LIVE Common Stock, par value $0.0001 per share 06/30/2026 0002007919 Inhibrx Biosciences, Inc. 45720N103 11025 N. Torrey Pines Road, Suite 140 La Jolla CA 92037 Rule 13d-1(b) Schonfeld Strategic Advisors LLC b DE 781678.00 0.00 781678.00 0.00 781678.00 N 5.33 IA The percentage of the issuer's common stock beneficially owned by the reporting person reflects 14,671,186 shares of common stock outstanding as of May 8, 2026, as set forth in the issuer's Quarterly Report on Form 10-Q for the period ended March 31, 2026, as filed with the Securities and Exchange Commission on May 14, 2026. Inhibrx Biosciences, Inc. 11025 N. Torrey Pines Road, Suite 140, La Jolla, California 92037 Schonfeld Strategic Advisors LLC ("Schonfeld") is an investment adviser to several private funds. Schonfeld also engages third party sub-advisers to manage assets of its private funds as separately managed accounts (the "Schonfeld SMAs"). Accordingly, Schonfeld may be deemed to indirectly beneficially own securities owned by the Schonfeld SMAs. Each Schonfeld SMA is the record and direct beneficial owner of a portion of the securities covered by this statement. Schonfeld declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934 or any other purpose, the beneficial owner of any securities covered by this statement. 590 Madison Avenue, 23rd Floor, New York, New York 10022 Delaware limited liability company Y 781,678 shares 5.33% 781,678 shares 0 shares 781,678 shares 0 shares Y N The securities held by each of the Schonfeld SMAs as to which this statement is filed are owned of record by clients of Schonfeld. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Schonfeld Strategic Advisors LLC /s/ Hung Luc 08/14/2026